Sponsored

Imugene’s (ASX: IMU) HER-Vaxx data presented at World Congress of Gastrointestinal Cancer - Kalkine Media

June 30, 2023 01:21 PM AEST | By Manisha
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Imugene’s new and significant HER-Vaxx data has been presented at the World Congress of Gastrointestinal Cancer in Barcelona.
  • The abstract presented was about ‘HERIZON: A Phase 2 study of HER-Vaxx (IMU-131)’.
  • The World Congress on Gastrointestinal Cancer has been the foundation for bringing forth progressive and innovative research work relating gastrointestinal cancer.

In the latest announcement, clinical-stage immuno-oncology company Imugene Limited (ASX: IMU) revealed that its latest HER-Vaxx data has been presented at the World Congress of Gastrointestinal Cancer in Barcelona.

Triggered by the ASX announcement, IMU shares jumped by over 7.8% and were trading at AU$0.096 at the time of writing on 30 June 2023, with a market capitalisation of AU$571.65 million.

Key details of the presentation

The abstract is titled, “HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER-2-targeting peptide vaccine plus SOC chemotherapy in patients with HER-2+ advanced stomach Cancer — Correlation of the antibody responses and clinical outcome.”

The presentation was delivered at the event by Dr Joshua Tobias, Medical University of Vienna, Austria on 29 June 2023 during a session titled ‘Basic Gastric Cancer – Biomarkers and Translational Research.’

Data source: IMU update

 

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.